UDP-Gal: N-acetylglucosamine β 1-4 galactosyltransferase expressing live attenuated parasites as vaccine for visceral leishmaniasis

Glycoconjugate Journal

Volumn 26, Issue 6 SPEC. ISS., 2009, Pages 663-673

  Bhaumik, Siddhartha Kumar ^a   Singh, Manoj Kumar ^a   Karmakar, Subir ^a   De, Tripti ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

Avirulent Leishmania donovani clonal parasite; Sterile protection; UDP galactose N acetylglucosamine 1 4 galactosyltransferase; Visceral leishmaniasis

Indexed keywords

ASIALO ALPHA ACID GLYCOPROTEIN; ASIALOGLYCOPROTEIN; GALACTOSE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; LEISHMANIA VACCINE; LIVE VACCINE; N ACETYLGALACTOSAMINE RECEPTOR; N ACETYLLACTOSAMINE SYNTHASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; CELLULAR IMMUNITY; CONFERENCE PAPER; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOPROPHYLAXIS; IMMUNOTHERAPY; KUPFFER CELL; LEISHMANIA DONOVANI; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMASTIGOTE; RABBIT; ROSETTE FORMATION; SPLEEN; T LYMPHOCYTE; TH1 CELL; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIBODY FORMATION; ANTIGENS, PROTOZOAN; ERYTHROCYTES; GALACTOSYLTRANSFERASES; IMMUNITY, CELLULAR; KUPFFER CELLS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIVER; MICE; MICE, INBRED BALB C; NITRIC OXIDE; PROTOZOAN VACCINES; RABBITS; REACTIVE OXYGEN SPECIES; SPLEEN; T-LYMPHOCYTES;

ANIMALIA; LEISHMANIA DONOVANI;

EID: 67651146729     PISSN: 02820080     EISSN: 15734986     Source Type: Journal    
DOI: 10.1007/s10719-008-9212-y     Document Type: Conference Paper

References (52)

1. P. Desjeux 2004 Leishmaniasis: current situation and new perspectives Comp. Immunol. Microbiol. Infect. Dis. 27 305 318
2. H.W. Murray 2001 Clinical and experimental advances in treatment of visceral leishmaniasis Antimicrob. Agents Chemother. 45 2185 2197
3. S.L. Croft 1988 Recent development in the chemotherapy of leishmaniasis Trends Pharmacol. Sci. 9 376 381
4. H.W. Murray J.D. Berman S.D. Wright 1988 Immunochemotherapy for intracellular Leishmania donovani infection: γ-interferon plus pentavalent antimony J. Infect. Dis. 157 973 978
5. F.J. Perez-Victoria S. Castanys F. Gamarro 2003 Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug Antimicrob. Agents Chemother. 47 2397 2403
6. P.J. Guerin P. Olliaro F. Nosten P. Druilhe R. Laxminarayan F. Binka W.L. Kilama N. Ford N.J. White 2002 Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development Lancet Infect. Dis. 2 564 573 (Pubitemid 34966359)
7. S. Sundar D.K. More M.K. Singh V.P. Singh S. Sharma A. Makharia P.C. Kumar H.W. Murray 2000 Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic Clin. Infect. Dis. 31 1104 1107
8. M. Grogl T.N. Thomason E.D. Franke 1992 Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease Am. J. Trop. Med. Hyg. 47 117 126
9. J.E. Jackson J.D. Tally W.Y. Ellis Y.B. Mebrahtu P.G. Lawyer J.B. Were S.G. Reed D.M. Panisko B.L. Limmer 1990 Quantitative in vitro drug potency and drug susceptibility evaluation of Leishmania spp. from patients unresponsive to pentavalent antimony Am. J. Trop. Med. Hyg. 43 464 480
10. H.W. Murray J.D. Berman C.R. Davies N.G. Saravia 2005 Advances in leishmaniasis Lancet. 366 1561 1577
11. R.N. Coler S.G. Reed 2005 Second-generation vaccines against leishmaniasis Trends Parasitol. 21 44 49
12. S.C. Mendonca D.G. Russell S.G. Coutinho 1991 Analysis of the human T cell responsiveness to purified antigens of Leishmania: lipophosphoglycan (LPG) and glycoprotein 63 (gp 63) Clin. Exp. Immunol. 83 472 478
13. E.A. Khalil A.M. El Hassan E.E. Zijlstra M.M. Mukhtar H.W. Ghalib B. Musa M.E. Ibrahim A.A. Kamil M. Elsheikh A. Babiker F. Modabber 2000 Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomized, double-blind, BCG-controlled trial in Sudan Lancet. 356 1565 1569
14. I. Sharifi A.R. FeKri M.R. Aflatonian A. Khamesipour A. Nadim M.R. Mousavi A.Z. Momeni Y. Dowlati T. Godal F. Zicker P.G. Smith F. Modabber 1998 Randomized vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran Lancet. 351 1540 1543
15. E. Handman 2001 Protective saliva: a novel approach to a Leishmania vaccine Trends Parasitol. 17 513 514
16. S.K. Bhaumik M. Singh R. Basu S. Bhaumik K. Roychoudhury K. Naskar S. Roy T. De 2008 Virulence attenuation of a UDP-galactose/N-acetylglucosamine beta1,4 galactosyltransferase expressing Leishmania donovani promastigote Glycoconj J. 25 459 472
17. L.A. Stauber 1958 Host resistance to Khartoum strain of Leishmania donovani Rice Inst. Pam. 45 80 83
18. P.C. Melby B. Chandrasekar W. Zhao J.E. Coe 2001 The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response J. Immunol. 166 1912 1920
19. T. De S. Roy 1999 Infectivity and attenuation of Leishmania donovani promastigotes: association of galactosyl transferase with loss of parasite virulence J. Parasitol. 85 54 59
20. J. Schlepper-Schäfer V. Kolb-Bachofen H. Kolb 1980 Analysis of lectin-dependent recognition of desialylated erythrocytes by Kupffer cells Biochem. J. 186 827 831
21. S. Mukhopadhyay S. Bhattacharyya R. Majhi T. De K. Naskar S. Majumdar S. Roy 2000 Use of an attenuated leishmanial parasite as an immunoprophylactic and immunotherapeutic agent against murine visceral leishmaniasis Clin. Diagn. Lab. Immunol. 7 233 240
22. S. Roy M.T. Scherer T.J. Briner J.A. Smith M.L. Gefter 1989 Murine MHC polymorphism and T cell specificities Science. 244 572 575
23. R.L. Coffman D.A. Lehman P. Rothman 1993 Mechanism and regulation of immunoglobulin isotype switching Adv. Immunol. 54 229 270
24. E. Handman 2001 Leishmaniasis: current status of vaccine development Clin. Microbiol. Rev. 14 229 243
25. A. Khamesipour S. Rafati N. Davoudi F. Maboudi F. Modabber 2006 Leishmaniasis vaccine candidates for development: a global overview Ind J. Med. Res. 123 423 438
26. H. Daneshvar G.H. Coombs P. Hagan R.S. Phillips 2003 Leishmania mexicana and Leishmania major: attenuation of wild-type parasites and vaccination with the attenuated lines J. Infect. Dis. 87 1662 1668
27. R.G. Titus F.J. Gueiros-Filho L.A. de Freitas S.M. Beverley 1995 Development of a safe live Leishmania vaccine line by gene replacement Proc. Natl. Acad. Sci. U. S. A. 92 10267 10271
28. R.M. Gorczynski 1985 Immunization of susceptible BALB/c mice against Leishmania braziliensis. I. Resistance induced using as immunogen adherent or nonadherent cells from infected mice Cell. Immunol. 94 1 10
29. B. Papadopoulou G. Roy M. Breton C. Kundig C. Dumas I. Fillion A.K. Singh M. Olivier M. Ouellette 2002 Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination Infect. Immun. 70 62 68
30. H. Daneshyar P. Hagan R.S. Phillips 2003 Leishmania mexicana H-line attenuated under pressure of gentamicin, potentiates a Th1 response and control of cutaneous leishmaniasis in BALB/c mice Parasite Immunol. 25 589 596
31. M. Calvopina P.A. Barroso J.D. Marco M. Korenaga P.J. Cooper S. Nonaka Y. Hashiguchi 2006 Efficacy of vaccination with a combination of Leishmania amastigote antigens and the lipid A-analogue ONO-4007 for immunoprophylaxis and immunotherapy against Leishmania amazonensis infection in a murine model of New World cutaneous leishmaniasis Vaccine. 24 5645 5652
32. S. Mukhopadhyay P. Sen S. Bhattacharyya S. Majumdar S. Roy 1999 Immunoprophylaxis and immunotherapy against experimental visceral leishmaniasis Vaccine. 17 291 300
33. F.Y. Liew C.A. O'Donnell 1993 Immunology of leishmaniasis Adv. Parasitol. 32 161 169
34. H.W. Galib J.A. Whittle M. Kubin F.A. Hashim A.M. el-Hassan K.H. Grabstein G. Trinchieri S.S. Reed 1995 IL-12 enhances Th1-type responses in human Leishmania donovani infections. J. Immunol. 154 4623 4629
35. A. Taylor Mur H.W. ray 1997 Intracellular antimicrobial activity in the absence of interferon-γ: effect of interleukin 12 in experimental visceral leishmaniasis in interferon-γ gene-disrupted mice J. Exp. Med. 185 1231 1239
36. L.C. Afonso T.M. Scharton L.Q. Vieira M. Wysocka G. Trinchieri P. Scott 1994 The adjuvant effect of interleukin-12 in a vaccine against Leishmania major Science. 263 235 7
37. K.J. Maloy F. Powrie 2001 Regulatory T cells in the control of immune pathology Nat. Immunol. 2 816 822 (Pubitemid 34906442)
38. K.J. Maloy L. Salaun R. Cahill G. Dougan N.J. Saunders F. Powrie 2003 CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms J. Exp. Med. 197 111 119
39. H. Himmelrich I. Maillard T. Biedermann F. Tacchini-Cottier R.M. Locksley M. Rocken J.A. Louis 2000 In BALB/c mice, IL-4 production during the initial phase of infection with Leishmania major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease J. Immunol. 164 4819 4825
40. P. Launois H. Himmelrich F. Tacchini-Cottier G. Milon J.A. Louis 1999 New insight into the mechanisms underlying Th2 cell development and susceptibility to Leishmania major in BALB/c mice Microbes Infect. 1 59 64 (Pubitemid 29364913)
41. J.M. Blackweell M.E. Ibrahim E.N. Miller C.S. Peacock E.A. Khalil H.J. Cordell J.M. Howson A.M. El Hassan R.E. Bereir J.M. Blackwell 2003 Genes Immun. 4 351 355
42. P. Kropf L.R. Schopf C.L. Chung D. Xu F.Y. Liew J.P. Sypek J.P. Muller 1999 Expression of Th2 cytokines and the stable Th2 marker ST2L in the absence of IL-4 during Leishmania major infection Eur. J. Immunol. 29 3621 3628
43. D. McMahon-Pratt J. Alexander 2004 Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease Immunol. Rev. 201 206 224
44. P.C. Melby A. Tabares B.I. Restrepo A.E. Cardona H.S. McGruff J.M. Teale 2001 Leishmania donovani: evolution and architecture of the splenic cellular immune response related to control of infection Exp. Parasitol. 99 17 25
45. H.W. Murray K.C. Flanders D.D. Donaldson J.P. Sypek P.J. Gotwals J. Liu X Ma 2005 Antagonizing deactivating cytokines to enhance host defense andchemotherapy in experimental visceral leishmaniasis Infect. Immun. 73 3903 3911
46. C. Bogdan 2008 Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example Cell. Microbiol. 10 1221 1234
47. D. Sacks S.L. Lal S.N. Shrivastava J. Blackwell F.A. Neva 1987 An analysis of T cell responsiveness in Indian kala-azar J. Immunol. 138 908 913
48. E. Pinelli R. Killick-Kendrick J. Wagenaar W. Bernadina G. del Real J. Ruitenberg 1994 Cellular and humoral immune responses in dogs experimentally and naturally infected with Leishmania infantum Infect. Immun. 62 229 235
49. R.T. Gazzinelli A. Talvani M.M. Camargo H.C. Santiago M.A. Oliveira L.Q. Vieira G.A. Martins J.C. Aliberti J.S. Silva 1998 Induction of cell-mediated immunity during early stages of infection with intracellular protozoa Braz. J. Med. Biol. Res. 31 89 104
50. S. Sundar M. Rai 2002 Laboratory diagnosis of visceral leishmaniasis Clin. Diag. Lab. Immunol. 9 951 958
51. E. Hamndman 1997 Leishmania vaccine: old and new Parasitol. Today. 13 236 238
52. T.W. Holbrook J.A. Cook E.W. Parker 1981 Immunization against Leishmania donovani: glucan as an adjuvant with killed promastigotes Am. J. Trop. Med. Hyg. 30 762 768